WJPR Citation New

  All Since 2011
 Citation  2903  2393
 h-index  27  24
 i10-index  68  60

Login

Best Paper Awards

World Journal of Pharmaceutical Research (WJPR) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.
            Best Paper Award :
Dr. Muhammad Baqir MR Fakhrildin
Download Article: Click Here

Search

Track Your Article

Abstract

A COMPARATIVE STUDY ON THE EFFECT OF HMG-CoA REDUCTASE INHIBITORS ON C-REACTIVE PROTEIN IN PATIENTS WITH ACUTE CORONARY SYNDROME

Mathew George, Lincy Joseph, Bincy.K.Chacko and Jess Jose

ABSTRACT

Objectives: The objectives of the study is to compare the effect of HMG-CoA reductase inhibitors (Atorvastatin 80mg and Rosuvastatin 40mg ) on hs-CRP, to evaluate the clinical outcome of the of HMGCoA reductase inhibitors and to document the adverse drug reaction (ADR) of HMG-CoA reductase inhibitors in patients with Acute Coronary Syndrome. Methods: This is a prospective experimental study conducted in 60 inpatients diagnosed with Acute Coronary Syndrome. The study population was divided into two groups. In each group, 30 patients were enrolled. One group included the patients who were taking Atorvastatin 80mg and the second group with Rosuvastatin 40mg. The hs-CRP levels, lipid profiles and adverse effects were measured at beginning and at the end of 2 weeks. Results: The HMG-CoA reductase inhibitors, atorvastatin 80mg and rosuvastatin 40mg reduces the hs-CRP levels significantly. Both atorvastatin and rosuvastatin have significant effect on lipid profile. There is significant difference in effect of atorvastatin and rosuvastatin in lowering of hs-CRP levels (P<0.001), lowering of LDL-C levels (P=0.01), elevating HDL-C levels (P=0.03), lowering TG levels (P < 0.001) and in reducing TC levels (P =0.036). Conclusion: Both atorvastatin 80 mg and rosuvastatin 40 mg are effective in decreasing hs-CRP, lowering of LDL-C levels, elevating HDL-C levels, lowering TG levels and in reducing TC levels. Rosuvastatin was found to be more effective in decreasing hs-CRP levels, lowering of LDLC levels, elevating HDL-C levels, lowering TG levels and in reducing TC levels. Thus this study throws light on the fact that rosuvastatin should be preferred over atorvastatin.

Keywords: Acute Coronary Syndrome, HMG-CoA reductase inhibitors, Atorvastatin, Rosuvastatin, C - Reactive Protein (CRP), High-Sensitivity C-Reactive Protein (hs-CRP).


[Full Text Article]

Call for Paper

World Journal of Pharmaceutical Research (WJPR)
Read More

Email & SMS Alert

World Journal of Pharmaceutical Research (WJPR)
Read More

Article Statistics

World Journal of Pharmaceutical Research (WJPR)
Read More

Online Submission

World Journal of Pharmaceutical Research (WJPR)
Read More